Scholarlink

<p>Experimental Autoimmune Myasthenia Gravis (EAMG) remains a cornerstone platform for mechanistic studies of pathogenic antibodies in myasthenia gravis (MG). In particular, monoclonal antibody passive-transfer EAMG (mAb-PTMG) has been instrumental in establishing causal links between defined antibody specificities and downstream neuromuscular junction (NMJ) dysfunction, as well as in dissecting key mechanisms underlying AChR antibody–mediated disease. More recently, PTMG studies using patient-derived MuSK monoclonal antibodies have expanded the mechanistic landscape of MG and provided an in vivo framework for evaluating the efficacy and mechanisms of action of agonistic anti-MuSK therapeutic antibodies. In this review, we summarize practical considerations for monoclonal antibody sourcing and preparation, standardized experimental workflows, major readouts and their interpretation, and representative applications across MG subtypes. We also highlight emerging opportunities for model refinement and translational application, with the aim of supporting mechanism-guided interpretation and the development of targeted antibody therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Monoclonal antibody passive experimental autoimmune myasthenia gravis: current progress and future directions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Liting Zheng,
  • Jianghao Wang,
  • Siying Tang,
  • Meiying Zhang,
  • Zheng Yu

摘要

Experimental Autoimmune Myasthenia Gravis (EAMG) remains a cornerstone platform for mechanistic studies of pathogenic antibodies in myasthenia gravis (MG). In particular, monoclonal antibody passive-transfer EAMG (mAb-PTMG) has been instrumental in establishing causal links between defined antibody specificities and downstream neuromuscular junction (NMJ) dysfunction, as well as in dissecting key mechanisms underlying AChR antibody–mediated disease. More recently, PTMG studies using patient-derived MuSK monoclonal antibodies have expanded the mechanistic landscape of MG and provided an in vivo framework for evaluating the efficacy and mechanisms of action of agonistic anti-MuSK therapeutic antibodies. In this review, we summarize practical considerations for monoclonal antibody sourcing and preparation, standardized experimental workflows, major readouts and their interpretation, and representative applications across MG subtypes. We also highlight emerging opportunities for model refinement and translational application, with the aim of supporting mechanism-guided interpretation and the development of targeted antibody therapies.